Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins - PubMed (original) (raw)
Comparative Study
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins
J J Weis et al. J Exp Med. 1988.
Erratum in
- J Exp Med 1988 Nov 1;168(5):1953-4
Abstract
Human complement receptor type 2 (CR2) is the B lymphocyte receptor for C3d and the Epstein-Barr virus. This protein is also a member of a family of C3b/C4b binding proteins that regulate complement activation, comprise tandemly repeated 60-75 amino acid sequences, and whose genes map to band q32 on chromosome 1. Overlapping cDNA clones encoding the entire human CR2 protein have been isolated from a human tonsillar cDNA library. The derived amino acid sequence of 1,032 residues encodes a peptide of 112,716 mol wt. A signal peptide was identified, followed by 15 copies of the short consensus repeat (SCR) structure common to the C3/C4 binding protein family. The entire extracellular portion of the protein comprised SCRs, thus, the ligand binding sites both for C3d and the EBV protein gp350/220 are positioned within this structure. Immediately following the final SCR was a transmembrane sequence of 24 amino acids and a cytoplasmic region of 34 amino acids. One of five cDNA clones isolated contained an additional SCR, providing evidence for alternative mRNA splicing or gene products of different human alleles. The CR2 cDNAs were used to isolate CR2-specific genomic phage. The entire CR2 coding sequences were found within 20 kb of human DNA. Analysis of the CR2 cDNA sequence indicated that CR2 contained internally homologous regions and suggested that CR2 arose by duplication of a primordial gene sequence encoding four SCRs. Comparison of the CR2 peptide sequence with those of other members of the gene family has identified many regions highly homologous with human CR1, fewer with C4bp and decay accelerating factor, and very few with factor H, and suggested that CR2 and CR1 arose by duplication of the same ancestral gene sequence. The homology between CR2 and CR1 extended to the transmembrane and cytoplasmic regions, suggesting that these sequences were derived from a common membrane-bound precursor.
Similar articles
- Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ, Fearon DT, Klickstein LB, Wong WW, Richards SA, de Bruyn Kops A, Smith JA, Weis JH. Weis JJ, et al. Proc Natl Acad Sci U S A. 1986 Aug;83(15):5639-43. doi: 10.1073/pnas.83.15.5639. Proc Natl Acad Sci U S A. 1986. PMID: 3016712 Free PMC article. - Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes.
Moore MD, Cooper NR, Tack BF, Nemerow GR. Moore MD, et al. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9194-8. doi: 10.1073/pnas.84.24.9194. Proc Natl Acad Sci U S A. 1987. PMID: 2827171 Free PMC article. - Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection.
Carel JC, Myones BL, Frazier B, Holers VM. Carel JC, et al. J Biol Chem. 1990 Jul 25;265(21):12293-9. J Biol Chem. 1990. PMID: 1695627 - Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21).
Ahearn JM, Fearon DT. Ahearn JM, et al. Adv Immunol. 1989;46:183-219. doi: 10.1016/s0065-2776(08)60654-9. Adv Immunol. 1989. PMID: 2551147 Review. No abstract available. - Complement receptors.
Holers VM. Holers VM. Year Immunol. 1989;4:231-40. Year Immunol. 1989. PMID: 2538973 Review. No abstract available.
Cited by
- The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
Fridkis-Hareli M, Storek M, Or E, Altman R, Katti S, Sun F, Peng T, Hunter J, Johnson K, Wang Y, Lundberg AS, Mehta G, Banda NK, Michael Holers V. Fridkis-Hareli M, et al. Mol Immunol. 2019 Jan;105:150-164. doi: 10.1016/j.molimm.2018.09.013. Epub 2018 Dec 1. Mol Immunol. 2019. PMID: 30513451 Free PMC article. - Tissue-targeted complement therapeutics.
Tomlinson S, Thurman JM. Tomlinson S, et al. Mol Immunol. 2018 Oct;102:120-128. doi: 10.1016/j.molimm.2018.06.005. Epub 2018 Jul 7. Mol Immunol. 2018. PMID: 30220307 Free PMC article. Review. - New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities.
Holers VM, Tomlinson S, Kulik L, Atkinson C, Rohrer B, Banda N, Thurman JM. Holers VM, et al. Semin Immunol. 2016 Jun;28(3):260-7. doi: 10.1016/j.smim.2016.05.007. Epub 2016 Jun 6. Semin Immunol. 2016. PMID: 27282113 Free PMC article. Review. - Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.
Kovacs JM, Hannan JP, Eisenmesser EZ, Holers VM. Kovacs JM, et al. J Biol Chem. 2010 Aug 27;285(35):27251-27258. doi: 10.1074/jbc.M110.106617. Epub 2010 Jun 17. J Biol Chem. 2010. PMID: 20558730 Free PMC article. - Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing.
Douglas KB, Windels DC, Zhao J, Gadeliya AV, Wu H, Kaufman KM, Harley JB, Merrill J, Kimberly RP, Alarcón GS, Brown EE, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Vilá LM, Gaffney PM, James JA, Moser KL, Alarcón-Riquelme ME, Vyse TJ, Gilkeson GS, Jacob CO, Ziegler JT, Langefeld CD, Ulgiati D, Tsao BP, Boackle SA. Douglas KB, et al. Genes Immun. 2009 Jul;10(5):457-69. doi: 10.1038/gene.2009.27. Epub 2009 Apr 23. Genes Immun. 2009. PMID: 19387458 Free PMC article.
References
- Proc Natl Acad Sci U S A. 1985 Nov;82(22):7711-5 - PubMed
- Proc Natl Acad Sci U S A. 1987 Dec;84(24):9194-8 - PubMed
- Lancet. 1986 Feb 1;1(8475):240-2 - PubMed
- FEBS Lett. 1986 Mar 3;197(1-2):353-6 - PubMed
- J Clin Immunol. 1986 Jan;6(1):65-73 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous